A phase I, open label, dose escalating study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending intravenous doses of catumaxomab in epithelial cancer patients

Cancer type: Solide tumores

Phase: I

Principal Investigator: Mau-Sørensen Morten

Country: DK

Keywords: Denmark, Rigshospitalet, EpCam, immunotherapy, fusion-antibody, solid tumor

Status: Completed

Link to